🔎 Trials Near Me

Home › Kanser sa Atay (Hepatocellular Carcinoma) › Tennessee

Pag-aaral pangklinika para sa Kanser sa Atay (Hepatocellular Carcinoma) sa Tennessee

14 pag-aaral para sa Kanser sa Atay (Hepatocellular Carcinoma) ang naghahanap ng mga kalahok sa mga site sa Tennessee.

Mga Lungsod sa Tennessee

Opisyal na teksto ng pag-aaral (English)

A Phase 1 Study of the Safety and Tolerability of CTX-10726

  • SCRI Oncology Partners, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07419841

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #3, Nashville
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05176483

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

  • Tennessee Oncology, Nashville
  • Vanderbilt University Medical Center, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07291076

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

  • Scri Oncology Partners, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 16, 2026 · NCT06427941

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Saint Jude Children's Research Hospital, Memphis
Nagre-recruitPhase 1/2
12 Months – 30 Years · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04851119

FOG-001 in Locally Advanced or Metastatic Solid Tumors

  • Sarah Cannon Research Institute, Nashville
  • Vanderbilt Ingram Cancer Center, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT05919264

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Erlanger Health, Inc, Chattanooga
  • The West Clinic, Germantown
  • SCRI Oncology Partners, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT06330064

A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

  • SCRI - TriStar Medical Group Children's Specialists, Nashville
  • SCRI Oncology Partners, Nashville
Nagre-recruitPhase 2
Edad 8 pataas · Lahat ng kasarian · Na-update Hul 27, 2026 · NCT05503797

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

  • St. Jude Children's Research Hospital, Memphis
Nagre-recruitPhase 1/2
Hanggang edad 30 · Lahat ng kasarian · Na-update May 19, 2026 · NCT05468359

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

  • The West Clinic, Germantown
  • University of Tennessee Medical Center, Knoxville
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 2, 2026 · NCT05733598

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

  • Research Site 136, Nashville
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 21, 2025 · NCT05914116

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Memphis
  • Massive Bio SYNERGY-AI site, Nashville
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

  • University of Tennessee Medical Center, Knoxville
Nagre-recruit
Edad 18 pataas · Lahat ng kasarian · Na-update Set 27, 2018 · NCT03686709

Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.